Other languages Bellerophon Therapeutics, Inc. Börse Stuttgart

Equities

6L7A

US0787713009

Market Closed - Börse Stuttgart Other stock markets 11:31:13 13/10/2023 am IST			5-day change	1st Jan Change
0.421 ^EUR	+20.98%		+26.05%	-45.08%

02/05	North American Morning Briefing : Stock Futures -2-	DJ
25/04	North American Morning Briefing : More Tech -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors	05/03
Bellerophon Therapeutics, Inc. Announces Executive Changes	22/11
Bellerophon Therapeutics, Inc. Announces Executive Changes	22/11
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing	17/23/17
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board	13/23/13
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading	28/23/28
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director	15/23/15
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023	30/23/30
Top Midday Decliners	05/23/05
Bellerophon's Phase 3 Study of INOpulse for Lung Disease Fails to Meet Primary Endpoint; Shares Plunge	05/23/05
Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease	05/23/05
Sector Update: Health Care Stocks Rising Late Friday	03/23/03
Sector Update: Health Care Stocks Rising Friday Afternoon	02/23/02
Bellerophon Therapeutics Files $150 Million Mixed Shelf	02/23/02
Bellerophon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease	11/23/11
Bellerophon Therapeutics, Inc. Announces Resignation of Nicholas Laccona as Principal Financial and Accounting Officer	26/23/26
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bellerophon Therapeutics, Inc. Börse Stuttgart

Equities

6L7A

US0787713009

Other languages

Filters